控制性卵巢过度刺激中的卵巢反应:血清FSH水平说明了什么?
在固定每日150 IU重组FSH方案下,比较不良、正常和高反应者的hCG触发日血清FSH水平。结果显示三组间无一致关系;校正年龄、体重、基础FSH和基础抗苗勒管激素后,触发日FSH与获卵数的相关性消失。作者认为不良反应与血清FSH水平本身无关,并建议未来研究评估剂量调整是否获益。
要点
- 固定150 IU rFSH方案下,hCG触发日血清FSH与卵巢反应无一致关系。
- 不良反应者触发日FSH与高反应者差异显著(P=0.03)。
- 校正年龄、体重、基础FSH和基础AMH后,触发日FSH与获卵数相关性消失。
核心结论
- 固定150 IU rFSH方案下,卵巢反应与hCG触发日血清FSH水平之间无一致关系。
- 不良反应与血清FSH水平本身无关,因此作者质疑对反应不佳者增加rFSH剂量是否有意义。
- 作者建议未来研究评估剂量调整是否使不良反应者和高反应者获益。
研究设计与样本
- 嵌套于随机对照试验的队列研究,2009年3月至2011年7月在University Medical Centre Utrecht开展。
- 纳入124名年龄≤39岁、月经规律、固定FSH剂量150 IU的女性,排除BMI>32 kg/m2及既往>2次IVF/ICSI失败者。
- 在周期第2天和hCG触发日采血,用Beckman-Coulter Unicel DXi800化学发光法测定血清FSH。
- 为检测不良、正常和高反应者间2 IU/L差异,共64名参与者(不良16、正常32、高反应16)可提供80%把握度,假设标准差为2、α为0.05。
主要发现
- 不良反应者(n=16)、正常反应者(n=94)和高反应者(n=17)的中位体重分别为70.0 kg(范围55.0-85.6)、68.0 kg(范围52.0-94)和60.6 kg(范围51.0-78.0)。
- hCG触发日血清FSH均值(标准差)在不良反应者为9.5 IU/L(2.4),正常反应者为10.4 IU/L(2.3),高反应者为11.5 IU/L(2.2)。
- 不良反应者与高反应者hCG触发日血清FSH水平差异显著(P=0.03)。
- 校正年龄、体重、基础血清FSH和基础抗苗勒管激素后,hCG触发日血清FSH与获卵数方面的卵巢反应之间的相关性消失。
临床怎么用
- 作者认为,不良反应与血清FSH水平本身无关,因此可质疑对反应不佳者增加rFSH剂量是否有意义。
- 作者提出,高反应者在后续IVF周期中降低rFSH剂量可能降低血清FSH水平,从而减轻卵巢反应并提高IVF治疗的安全性。
- 作者建议未来研究评估剂量调整是否使不良反应者和高反应者获益。
局限性
- 获卵数仅极小程度由hCG触发日血清FSH水平决定。
- 校正年龄、体重、基础血清FSH和基础抗苗勒管激素后,hCG触发日血清FSH与获卵数方面的卵巢反应之间的相关性消失。
- 本研究非剂量-反应研究,未来研究应评估剂量调整是否使不良反应者和高反应者获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do serum FSH levels on day of hCG trigger differ between women with a poor, normal or hyper response to a fixed daily dose of 150 IU recombinant FSH (rFSH)? SUMMARY ANSWER: There is no consistent relationship between ovarian response and serum FSH levels on day of hCG trigger in a 150 IU fixed dose treatment protocol. WHAT IS KNOWN ALREADY: When ovarian response to stimulation for IVF/ICSI is suboptimal, the FSH dose is often adjusted in a subsequent cycle, thereby assuming that serum FSH levels were inadequate for optimal stimulation. STUDY DESIGN, SIZE, DURATION: Nested cohort study within a randomized controlled trial conducted at the University Medical Centre Utrecht between March 2009 and July 2011. Blood was drawn from 124 women on cycle Day 2 and on day of hCG triggering. Serum FSH level was determined by the Beckman-Coulter Unicel DXi800 chemiluminescence assay. In order to detect a difference of 2 IU/L between poor, normal and hyper responders, a total of 64 participants (16 poor, 32 normal and 16 hyper responders) would provide 80% power, assuming a standard deviation of 2 and an alpha of 0.05. PARTICIPANTS, SETTING, METHODS: Women aged ≤39 years with a regular cycle and fixed FSH dose of 150 IU. Exclusion criteria: BMI > 32 kg/m2 and >2 previous unsuccessful IVF/ICSI cycles. The primary outcome measure was serum FSH level on day of triggering. MAIN RESULTS AND THE ROLE OF CHANCE: Median [range] body weight was 70.0 kg [55.0-85.6], 68.0 kg [52.0-94] and 60.6 kg [51.0-78.0] for poor (n = 16), normal (n = 94) and hyper (n = 17) responders, respectively. Mean (SD) serum FSH levels on day of triggering were 9.5 IU/L (2.4) in poor, 10.4 IU/L (2.3) in normal and 11.5 IU/L (2.2) in hyper responders. Serum FSH levels on day of hCG in poor responders differed significantly as compared to those in hyper responders (P = 0.03). LIMITATIONS, REASONS FOR CAUTION: The number of retrieved oocytes is only minimally determined by serum FSH level on the day of hCG trigger. After correction for age, body weight, basal serum FSH and basal anti-Mullerian hormone the correlation between serum FSH level on the day of hCG and ovarian response regarding the number of retrieved oocytes disappeared. WIDER IMPLICATIONS OF THE FINDINGS: The current study shows that a poor response is not related to inadequate serum FSH levels per se. One could therefore question whether increasing the rFSH dose in women with a suboptimal response is meaningful. In women with a hyper response, however, lowering the dose of rFSH in a subsequent IVF cycle may lead to lower serum FSH levels and thereby mitigate ovarian response and improve safety of the IVF treatment. As this was not a dose-response study, future research should assess whether dose adjustments benefit the poor and hyper responder. STUDY FUNDING/COMPETING INTEREST(S): No external funds were obtained for this study. S.C.O, T.C.v.T., O.H., H.L.T., E.G.W.M.L., C.B.L. and M.J.C.E. have nothing to disclose. F.J.M.B. receives monetary compensation: member of the external advisory board for Merck Serono and Ferring, the Netherlands; educational activities for Ferring BV, the Netherlands; consultancy work for Gedeon Richter, Belgium; strategic cooperation with Roche on automated AMH assay development and research cooperation with Ansh Labs.
引用
- Oudshoorn SC, van Tilborg TC, Hamdine O, et al. Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say? Hum Reprod. 2017. PMID: 28854580. doi:10.1093/humrep/dex222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。